An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Published:2015 Issue: Volume:4 Page:192-195
ISSN:2213-0896
Container-title:Cancer Treatment Communications
language:en
Short-container-title:Cancer Treatment Communications

Author:

Lin Jianqing,Deng Aileen,Hoffman-Censits Jean,Gibney Geoffrey,Hyslop Terry,Miller Brooke,Kilpatrick Deborah,Jabbour Serge,Kevin Kelly William

Publisher

Elsevier BV

Subject

Oncology

Reference41 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N. Engl. J. Med. [Internet],2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N. Engl. J. Med. [Internet],2004

3. The hallmarks of castration-resistant prostate cancers;Katsogiannou;Cancer Treat. Rev. [Internet],2015

4. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer;Bitting;Endocr. Relat. Cancer [Internet],2013

5. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP